- Home
- REVB vs CISS Comparison
REVB vs CISS Comparison
Compare REVB & CISS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVB
- CISS
- Stock Information
- Founded
- REVB 2020
- CISS 2022
- Country
- REVB United States
- CISS Greece
- Employees
- REVB N/A
- CISS N/A
- Industry
- REVB Biotechnology: Pharmaceutical Preparations
- CISS Marine Transportation
- Sector
- REVB Health Care
- CISS Consumer Discretionary
- Exchange
- REVB Nasdaq
- CISS Nasdaq
- Market Cap
- REVB 2.6M
- CISS 3.1M
- IPO Year
- REVB N/A
- CISS N/A
- Fundamental
- Price
- REVB $3.05
- CISS $3.65
- Analyst Decision
- REVB
- CISS
- Analyst Count
- REVB 0
- CISS 0
- Target Price
- REVB N/A
- CISS N/A
- AVG Volume (30 Days)
- REVB 39.6K
- CISS 34.9K
- Earning Date
- REVB 05-08-2025
- CISS 05-15-2025
- Dividend Yield
- REVB N/A
- CISS N/A
- EPS Growth
- REVB N/A
- CISS N/A
- EPS
- REVB N/A
- CISS N/A
- Revenue
- REVB N/A
- CISS $38,174,754.00
- Revenue This Year
- REVB N/A
- CISS N/A
- Revenue Next Year
- REVB N/A
- CISS N/A
- P/E Ratio
- REVB N/A
- CISS N/A
- Revenue Growth
- REVB N/A
- CISS N/A
- 52 Week Low
- REVB $2.36
- CISS $2.85
- 52 Week High
- REVB $60.80
- CISS $29.40
- Technical
- Relative Strength Index (RSI)
- REVB 49.28
- CISS 43.67
- Support Level
- REVB $2.87
- CISS $3.62
- Resistance Level
- REVB $3.32
- CISS $3.97
- Average True Range (ATR)
- REVB 0.20
- CISS 0.31
- MACD
- REVB 0.02
- CISS 0.01
- Stochastic Oscillator
- REVB 47.18
- CISS 15.79
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
About CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of our fleet is approximately 64,000 dwt.